drugset / Trial / NCT05014438
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.
Timeline
- Start
- 2021-08-17
- Primary completion
- 2022-08-22
- Completion
- 2022-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986166 | Small molecule | — | — |
| Subject | Branebrutinib | Small molecule | — | — |